XML 54 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Mar. 10, 2023
Cover [Abstract]    
Document Type 10-K  
Amendment Flag false  
Document Period End Date Dec. 31, 2022  
Entity Registrant Name IKENA ONCOLOGY, INC.  
Entity Central Index Key 0001835579  
Entity Incorporation, State or Country Code DE  
Entity File Number 001-40287  
Entity Tax Identification Number 81-1697316  
Entity Address, Address Line One 645 Summer Street  
Entity Address, Address Line Two Suite 101  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02210  
City Area Code 857  
Local Phone Number 273-8343  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus FY  
Entity Current Reporting Status Yes  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Shell Company false  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Interactive Data Current Yes  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol IKNA  
Security Exchange Name NASDAQ  
Document Annual Report true  
Document Transition Report false  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
ICFR Auditor Attestation Flag false  
Entity Common Stock, Shares Outstanding   36,257,493
Entity Public Float $ 58.0  
Auditor Name Ernst & Young LLP  
Auditor Location Boston, Massachusetts  
Auditor Firm ID 42  
Documents Incorporated by Reference

Portions of the registrant’s proxy statement for the 2023 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant’s fiscal year ended December 31, 2022, are incorporated by reference in Part III of this Form 10-K.